New targeted drug trial offers hope for Tough-to-Treat cancers
NCT ID NCT04683250
Summary
This clinical trial is testing an experimental drug called TAS0953/HM06 for people with advanced solid tumors that have specific RET gene abnormalities. The study aims to find the safest and most effective dose of the drug and see how well it shrinks tumors in patients with cancers like non-small cell lung cancer and other solid tumors. Participants will receive the drug and be closely monitored for side effects and tumor response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RET-ALTERED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chao Family Comprehensive Cancer Center
TERMINATEDOrange, California, 92868-3298, United States
-
Henry Ford Hospital
TERMINATEDDetroit, Michigan, 48202, United States
-
Kanagawa Cancer Center
RECRUITINGKanagawa, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kansai Medical University Hospital
RECRUITINGHirakata-shi, Osaka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kurashiki Central Hospital
RECRUITINGOkayama, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
TERMINATEDNew York, New York, 10016, United States
-
Massachusetts General Hospital
TERMINATEDBoston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
TERMINATEDNew York, New York, 10065, United States
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
RECRUITINGKashiwa-shi, Chiba, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Hospital Organization Kyushu Cancer Center
RECRUITINGFukuoka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Okayama University Hospital
RECRUITINGOkayama, Okayama-ken, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Osaka International Cancer Institute
RECRUITINGOsaka, Osaka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Midwest - Cancer & Hematology Centers of Western Michigan
TERMINATEDGrand Rapids, Michigan, 49546, United States
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shizuoka Cancer Center
RECRUITINGShizuoka, Shizuoka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford Cancer Center
TERMINATEDStanford, California, 94305-5826, United States
-
The Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Sarah Cannon Research Institute/Tennessee Oncology
TERMINATEDNashville, Tennessee, 37203, United States
-
The University of Texas M. D. Anderson Cancer Center
TERMINATEDHouston, Texas, 77030-4009, United States
-
Tohoku University Hospital
RECRUITINGSendai, Miyagi, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.